The safety of anticholinergic bronchodilators for the treatment of chronic obstructive pulmonary disease (Q38592062)

4 September 2017

The safety of anticholinergic bronchodilators for the treatment of chronic obstructive pulmonary disease (English)

1 reference

chronic obstructive pulmonary disease

4 September 2017

1 reference

D P Tashkin

1

1 reference

PubMed ID

26401729

4 September 2017

language of work or name

English

0 references

publication date

24 September 2015

1 reference

Expert Opinion on Drug Safety

4 September 2017

1 reference

4 September 2017

14

1 reference

4 September 2017

11

1 reference

4 September 2017

1759-1772

1 reference

Epidemiology of Chronic Obstructive Pulmonary Disease: Prevalence, Morbidity, Mortality, and Risk Factors

4 September 2017

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

A 4-year trial of tiotropium in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Therapeutic responses in asthma and COPD. Bronchodilators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Bronchodilator reversibility testing in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Inhaled glycopyrronium bromide: a review of its use in patients with moderate to severe chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Umeclidinium/vilanterol: a review of its use as maintenance therapy in adults with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Muscarinic receptor subtypes in airways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Acetylcholine beyond neurons: the non-neuronal cholinergic system in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Comorbidities and Chronic Obstructive Pulmonary Disease: Prevalence, Influence on Outcomes, and Management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Hospitalizations and mortality in the Lung Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Lack of association between ipratropium bromide and mortality in elderly patients with chronic obstructive airway disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Ipratropium and lung health study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Tiotropium 5microg via Respimat and 18microg via HandiHaler; efficacy and safety in Japanese COPD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Tiotropium Respimat inhaler and the risk of death in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Tiotropium HandiHaler in the treatment of COPD: a safety review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Tiotropium for the treatment of stable chronic obstructive pulmonary disease: a systematic review with meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Tiotropium and risk for fatal and nonfatal cardiovascular events in patients with chronic obstructive pulmonary disease: systematic review with meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Cardiovascular safety of tiotropium in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Cardiac safety of tiotropium in patients with cardiac events: a retrospective analysis of the UPLIFT® trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Inhaled anticholinergic agents and acute urinary retention in men with lower urinary tract symptoms or benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Tiotropium for stable chronic obstructive pulmonary disease: A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Limited generalisability of UPLIFT findings to clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Cardiovascular and respiratory hospitalizations and mortality among users of tiotropium in Denmark.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

A one-year trial of tiotropium Respimat plus usual therapy in COPD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Use of tiotropium Respimat Soft Mist Inhaler versus HandiHaler and mortality in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Risks associated with tiotropium in chronic obstructive pulmonary disease: overview of the evidence to date

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Safety of inhaled glycopyrronium in patients with COPD: a comprehensive analysis of clinical studies and post-marketing data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinol esters as potent and long-acting muscarinic antagonists with potential for minimal systemic exposure after inhaled administration: identification of (3R)-3-{[hydroxy(di-2-thien

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Long-term safety and efficacy of twice-daily aclidinium bromide in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Safety, tolerability, pharmacodynamics and pharmacokinetics of umeclidinium and vilanterol alone and in combination: a randomized crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

The problems of anticholinergic adverse effects in older patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Inhaled Anticholinergic Drug Therapy and the Risk of Acute Urinary Retention in Chronic Obstructive Pulmonary Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1093621

10.1517/14740338.2015.1093621

21 January 2018

Identifiers

DOI

1 reference

4 September 2017

1 reference

PubMed ID

26401729